The "Ewing Sarcoma Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, …
Agenus ... Celldex's vaccine failure was one of 2016's worst: Rintega performed as expected, but the control group receiving standard chemo did unusually well. It looks like the heavy losses left bruises that the market isn't ready to …
Celldex Therapeutics (NASDAQ: CLDX) saw its stock take a huge nosedive in 2016. That's what happens when your lead product flops in a late-stage clinical study. Did anything go right for the company this year? Actually, yes. Here's …
It looks like the heavy losses left bruises that the market isn't ready to forget, and the stock has yet to recover. That could change before too long. Celldex has another candidate approaching the finish line, called glemba, that is entirely …